cTnI determination aids in the diagnosis of myocardial infarction (MI) (1,2) and patients with non-ST-segment elevation (NSTEMI) acute coronary syndrome (ACS) (3,4). Elevated cTnI levels in the NSTEMI ACS sub-population correlate with the relative risk of mortality, MI or increased probability of ischemic events requiring urgent revascularization procedures. For patients with chronic or acute decompensated heart failure (HF), measurements of cTnI provide complementary information to assist in patient evaluation and management.
From a population of 224 individuals, the IB10 sphingotest® Troponin-99 test was used to determine the concentration upper reference limits of cTnI. This population included apparently healthy individuals.
Upper Reference Limit:
The 99th percentile upper reference limit is 0.10 ng/mL. Each laboratory should establish a reference range that represents the patient population that is to be evaluated at their facility.
Whole Blood vs. Plasma Comparison
All our assays correlate with r=0.9. For more detailed information please read the IFUs or connect with our sales representatives.
(1) Reichlin T et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011; 124:136–145.
(2) Thygesen K et al. Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007 Nov 27;50(22):2173-95.
(3) Babuin L et al. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ. 2005 Nov 8;173(10):1191-202.
(4) Larue C et al. Cardiac-specific immunoenzymometric assay of troponin I in the early phase of acute myocardial infarction. Clin Chem. 1993 Jun;39(6):972-9.